Le Lézard
Classified in: Health, Science and technology, Business
Subjects: ERN, TRI

Alligator Bioscience AB (publ) Interim Report January-March 2019


STOCKHOLM, April 17, 2019 /PRNewswire/ -- Significant events January-March

Events after the end of the period

Financial information

January-March 2019

  • Total operating costs SEK -46.7 million (-45.0)
  • Operating result, SEK -46.2 million (-44.0)
  • Earnings per share before and after dilution, SEK -0.62 (-0.59)
  • Cash flow for the period, SEK -34.3 million (0.8)
  • Cash and cash equivalents, including securities, SEK 402.9 million (436.4)

    • "This is a very exciting year for Alligator. We currently have two projects ? ADC-1013 and ATOR-1015 ? in clinical development. These projects will soon be joined by ATOR-1017," CEO Per Norlén comments.

    Read the complete report in the pdf below.

    The information was submitted for publication at 8:00 a.m. CEST on April 17, 2019.

    For further information, please contact:

    Per Norlén
    CEO
    [email protected]
    046-540-82-00

    Per-Olof Schrewelius
    CFO
    [email protected]
    046-540-82-03

    Cecilia Hofvander
    Director IR & Communications
    [email protected]
    046-540-82-06

    Alligator Bioscience AB (publ) 556597-8201
    Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden
    Phone +46-46-540-82-00
    www.alligatorbioscience.com

    About Alligator Bioscience

    Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's growing pipeline includes five lead clinical and preclinical drug candidates: ADC-1013, ATOR-1015, ATOR-1017, ALG.APV-527 and ATOR-1144. Alligator's shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit www.alligatorbioscience.com.

    ADC-1013 (JNJ-7107) is licensed to Janssen Biotech, Inc. for global development and commercialization.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/alligator-bioscience/r/alligator-bioscience-ab--publ--interim-report-january-march-2019,c2789720

    The following files are available for download:

    https://mb.cision.com/Main/12681/2789720/1027439.pdf

    Alligator Bioscience AB (publ) Interim report January-March 2019

    SOURCE Alligator Bioscience


    These press releases may also interest you

    at 23:03
    TaiGen Successfully Completes TG-1000 Phase III Study
    TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...

    at 20:00
    SysInformation Healthcare Services, LLC Provides Notice of a Data Security Event
    SysInformation Healthcare Services, LLC ("SysInformation"), d/b/a EqualizeRCM and 1st Credentialing, is providing notice of a recent data security event that may affect the security of information related to certain individuals. SysInformation is...

    at 19:32
    Scottie Resources Announces Grant of Stock Options
    Scottie Resources Corp. ("Scottie" or the "Company") announces that it has granted 7,400,000 options to acquire common shares to certain directors, officers, and consultants to the Company. The options are exercisable at a price of $0.195 per...

    at 19:31
    DaVita Inc. Schedules 1st Quarter 2024 Investor Conference Call
    DaVita Inc. , announced today that it will hold its quarterly conference call to discuss first quarter results on Thursday, May 2, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is...

    at 18:05
    Grady to Build Freestanding Emergency Department in South Fulton County
    As part of its ongoing mission to meet the growing need for emergency services in metro Atlanta, Grady Health System will build a freestanding emergency department in south Fulton County. This freestanding emergency department, built in partnership...

    at 18:00
    Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures
    Digicann Ventures Ltd. ("Digicann" or the "Company") , a company focused on opportunities within and outside of the cannabis industry, announces that it has entered into an agreement with holders of the Company's 10.00% Senior Unsecured Convertible...

    More news about Health...


    News published on and distributed by: